Sponsor content
353 result(s) found, displaying 1 to 10
-
Australian Public Assessment Report (AusPAR)Enflonsia (clesrovimab) is approved for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season. Enflonsia should be used in accordance with official recommendations.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for KEYTRUDA SC pembrolizumab 395 mg/ 2.4 mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for KEYTRUDA SC pembrolizumab 790 mg/ 4.8 mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ENFLONSIA clesrovimab 105 mg in 0.7 mL solution for injection prefilled syringe.
-
Apr-2026Prescription medicine evaluationActive ingredient: pembrolizumab.
-
Apr-2026Prescription medicine evaluationActive ingredient: pembrolizumab.
-
Apr-2026Prescription medicine evaluationActive ingredient: pembrolizumab.
-
Apr-2026Prescription medicine evaluationActive ingredient: belzutifan.
-
Prescription medicine decision summaryEnflonsia has been approved to help prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd